Saturday 17 October 2026
Export KRSA’s income statement to Excel — free account
Korsana Biosciences, Inc.
KRSA Healthcare Biotechnology
In the quarter to June 2026, revenue fell 43.2%, EPS fell 272.7% and free cash flow fell 184.7%, each against the same quarter a year earlier. Operating cash flow growth for three consecutive years.
32.38
1.27
−3.77%
Follow KRSA
| Older periods | Sep '25 | Dec '25 | Mar '26 | Jun '26 | |
|---|---|---|---|---|---|
P/E ratio |
+8 more quarters Free account |
0.00 | 0.00 | — | — |
P/S ratio |
2.60 | 1.95 | — | — | |
P/FCF ratio |
90.49 | 0.00 | — | — | |
P/Operating CF |
(28.11) | (2.56) | — | — | |
P/B ratio |
0.78 | 0.44 | — | — | |
Price to Tangible BV |
0.78 | 0.44 | — | — | |
EV/Sales |
1.00 | 0.39 | — | — | |
EV/EBITDA |
0.00 | 0.00 | — | — | |
EV/Operating CF |
(2.07) | (0.24) | — | — | |
EV/FCF |
34.79 | (0.43) | — | — | |
Quick Ratio |
5.32 | 4.71 | 1.65 | 0.75 | |
Current Ratio |
5.78 | 5.15 | 1.80 | 0.82 | |
Net Debt/EBITDA |
4.54 | 3.87 | 0.88 | 0.79 | |
Debt/Assets |
0.00% | 0.00% | 0.00% | 0.00% | |
Debt/Equity |
0.00 | 0.00 | 0.00 | 0.00 | |
Asset Turnover |
0.30 | 0.21 | 0.00 | 0.00 | |
Operating CF/Net income |
0.27 | 1.98 | 0.37 | 0.82 | |
Capex/Depreciation |
— | — | 0.00 | 0.00 | |
Research and Development Expense of Revenue |
39.77% | 50.63% | 0.00% | — | |
Selling, General and Administrative Expense of Revenue |
175.20% | 131.12% | 0.00% | 0.00% | |
Intangible Assets out of Total Assets |
0.00 | 0.00 | 0.00 | 0.00 | |
Share Based Compensation of Revenue |
13.49% | 9.27% | 0.00% | 0.00% | |
Graham Net Nets |
0.56 | 0.92 | — | — | |
Graham Number |
0.00 | 0.00 | — | — | |
Earnings Yield |
(32.60%) | (91.31%) | — | — | |
Free Cash Flow Yield |
1.11% | (45.95%) | — | — | |
Revenue per Share |
1.90 | 2.25 | 0.00 | 0.00 | |
Operating CF per Share |
(0.57) | (3.47) | (1.96) | (2.36) | |
Capex per Share |
0.00 | 0.00 | (0.11) | 0.00 | |
Free Cash Flow per Share |
(0.57) | (3.47) | (2.07) | (2.36) | |
Cash per Share |
9.91 | 7.13 | 4.70 | 2.29 | |
Shareholders Equity per Share |
20.69 | 19.98 | 11.30 | 8.37 | |
Interest Debt per Share |
0.00 | 0.00 | 0.00 | 0.00 | |
Book value per Share |
20.69 | 19.98 | 11.30 | 8.37 | |
Free Cash Flow |
(0.26) | (1.58) | (1.24) | (1.43) | |
Working Capital |
4.19 | 3.74 | 1.38 | (0.33) | |
Capital Expenditures |
— | — | (0.07) | 0.00 | |
Net Current Asset Value |
4.19 | 3.74 | 1.38 | (0.33) | |
EV/EBIT |
0.00 | 0.00 | — | — | |
Capex to Sales |
0.00 | 0.00 | 0.00 | 0.00 | |
Price to Operating Income |
0.00 | 0.00 | — | — | |
| Other line items | |||||
Average Receivables |
0.07 | 0.78 | — | — | |
Average Payables |
0.39 | 0.45 | 0.47 | 1.03 | |
Average Assets |
9.66 | 9.78 | 9.18 | 8.15 | |
Average Common Equity |
8.87 | 8.97 | 7.79 | 6.83 |
Columns are period end dates